Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, University of Washington, dissects the limited data on T-cell therapies for multiple myeloma, infectious complications, and access to specialized treatment centers.
There are limited randomized data on studies that focus on T-cell–directed therapies in the first-line setting for multiple myeloma. However, the ongoing CARTITUDE-5 and CARTITUDE-6 studies are comparing chimeric antigen receptor (CAR) T-cell therapies with traditional treatments, said Rahul Banerjee, MD, FACP, assistant professor for the Division of Hematology and Oncology at the University of Washington.
Banerjee attended the annual International Myeloma Society conference to discuss how to determine the type of T-cell–directed therapies to use for patient populations. Although newer CAR T-cell therapies are expected to be more effective based on less T-cell exhaustion, he expressed concerns regarding infectious complications and the unmet need for specialized centers that are equipped to treat CAR T-cell therapies.
The CARTITUDE-5 study is comparing the efficacy of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) vs VRd induction followed by lenalidomide and dexamethasone maintenance in newly diagnosed patients with multiple myeloma.
Banerjee also addressed the CARTITUDE-6 study that is comparing the efficacy of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) followed by cilta-cel vs DVRd followed by autologous stem cell transplant in newly diagnosed patients with multiple myeloma.
"Bispecifics are also being explored in the front-line setting. There are several studies that have been looking at this; MajesTEC-7 comes to mind."
Banerjee explains the purpose of MajesTEC-7 was to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide and talquetamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone.
Additionally, he mentions the MAIA study as an example where bispecifics were explored in a front-line setting. Banerjee states that although the study results thus far have shown some success, the risk of infections was found to be greater than he would like them to be, and he suggests the safety profiles of the drugs should be examined further.
"Even if tomorrow, teclistamab were to be approved for front-line therapy in any subset of patients, I would hazard a guess that 90% of Americans do not live within 30 minutes of a bispecific-capable center."
Banerjee concludes the interview by recognizing the specific outpatient dosing they have access to but how this falls short on a global scale.
"I do want to put a very clear note of caution there that we need to look before we leap into this world of BCMA [B-cell maturation antigen] as front-line therapy."
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More